Clinical Trial Update: Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating Niraparib in combination with anti-PD-1 therapy for recurrent ovarian carcinosarcoma and endometrial carcinosarcoma is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinosarcoma
• Ovarian Carcinosarcoma

Drugs mentioned

• Anti-PD-1 antibody
• Niraparib (Niraparib)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2, Phase 3 | Status: RECRUITING